Synaptogenix announces phase 2b nih sponsored alzheimer's disease trial update

New york, june 9, 2021 /prnewswire/ -- synaptogenix, inc. (nasdaq: snpx), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced an update on its ongoing national institutes of health ("nih") sponsored phase 2b clinical trial of bryostatin-1 in patients suffering from moderately severe alzheimer's disease ("ad"). to date, the company has now dosed 58 of its target 100 patients.
SNPX Ratings Summary
SNPX Quant Ranking